Abstract:

BACKGROUND: Experimental studies have shown that polyanhydride-pirarubicin implants can maintain relatively constant blood concentration for a long term.
OBJECTIVE: To observe the in vivo antitumor effect of polyanhydride-pirarubicin implants in the bladder tumors in rats.
METHODS: Sprague-Dawley rat bladder cancer models were built by the N-butyl-N-(4-hydroxy-butyl) nitrosamine feeding, and then were randomly divided into experimental and control groups. Polyanhydride-pirarubicin implants and the same dose of pirarubicin implants were implanted into the bladder submucosathe of rat models. High performance liquid chromatography detection was done for monitoring plasma concentration and changes in tumor size.
RESULTS AND CONCLUSION: In the experimental group, there was no burst effect during the release of pirarubicin, basically meeting the requirements of long-acting local implants used in the treatment of bladder cancer (sustained release of over 80 days). In the control group, pirarubicin concentration significantly increased firstly, then decreased rapidly after 5 days and it was unable to maintain the effective therapeutic concentrations (1.0-3.0 mg/L). Thirty days after implantation, the tumor size in the experimental group was significantly reduced, and the inhibition rate in the experimental group was higher than that in the control group (P < 0.05). Rats in the experimental group had a longer average survival period than those in the control group (P < 0.05).